Intratracheal myriocin enhances allergen-induced Th2 inflammation and airway hyper-responsiveness. ↗
Edukulla R, Rehn KL, Liu B, McAlees JW, Hershey GK, Wang YH, Lewkowich I, Lindsley AW.
Vad undersöktes?
- Hur undersöktes det?
- Utilizing myriocin, a potent inhibitor of sphingolipid synthesis, we evaluated the immune regulatory role of de novo ceramide generation in vitro and in vivo.
- Vilka undersöktes?
- BALB/C mice
- Vilken ämnesform?
- intratracheal myriocin
- Vilken mängd användes?
- 1.2 μg/intratracheal dose
- Hur länge pågick studien?
- serially immunized intratracheally every 48 h for 2 weeks
Studieuppgifterna återges som originalcitat. Uppgifter som saknas här kan finnas i originalutdraget.
Vad kom studien fram till?
Författarna rapporterar att intratrakealt myriocin hämmade SPT-aktivitet och minskade ceramidnivåer i lungvävnad hos möss. Enbart myriocin gav ingen signifikant ökning av luftvägshyperreaktivitet, medan samtidig behandling med HDM och myriocin förstärkte HDM-inducerad luftvägshyperreaktivitet och inflammation i musmodellen.
Vad behöver resultatet vägas mot?
Underlaget omfattar endast utvalda artikelstycken; resultaten gäller en musmodell och några slutsatser om effekt hos människor kan inte dras.
Läs de originalstycken som sammanställningen bygger på
MethodsUtilizing myriocin, a potent inhibitor of sphingolipid synthesis, we evaluated the immune regulatory role of de novo ceramide generation in vitro and in vivo. Intratracheal myriocin was administered alone or during house dust mite sensitization (HDM) of BALB/C mice and airway hyper‐responsiveness (AHR) was evaluated by invasive plethysmography followed by bronchial lavage (BAL) cytology and cytokine quantification.
ResultsMyriocin inhibits and HDM exposure activates de novo ceramide synthesis in bone marrow‐derived dendritic cells. Mice receiving intratracheal myriocin developed a mild airway neutrophilic infiltrate without inducing a significant increase in AHR. CXCL1 was elevated in the BAL fluid of myriocin‐treated mice while the neutrophilic chemotactic factors anaphylatoxin C5a, leukotriene B4, and IL‐17 were unaffected. HDM treatment combined with myriocin led to a dramatic enhancement of AHR (63% increase over HDM alone, p < 0.001) and increased granulocyte pulmonary infiltrates versus HDM or myriocin alone. Elevated Th2 T cell counts and Th2 cytokines/chemokines (IL5, IL13, CCL17) were observed in mice treated with combined HDM/myriocin compared to HDM alone. Myriocin‐treated pulmonary CD11c+ cells stimulated with HDM secreted significantly more CXCL1 than cells stimulated with HDM alone while HDM stimulated airway epithelial cells showed no change in CXCL1 secretion following myriocin treatment.
Animals, immunizations, and materialsSeven‐ to eight‐week‐old BALB/c mice were purchased from Jackson Laboratory (Bar Harbor, ME), maintained in a specific pathogen free facility at Cincinnati Children's Hospital Medical Center (CCHMC) and handled under Institutional Animal Care and Use Committee‐approved procedures. Following isoflourane anesthesia, animals underwent allergen immunization as previously described with the following modifications: mice were serially immunized intratracheally every 48 h for 2 weeks with low‐endotoxin, low‐dose HDM extract (D. pteronyssinus, Greer Labs; Lenoir, NC) (3 μg total protein/dose in 50 μL of sterile phosphate‐buffered saline plus vehicle [PBS]). Myriocin (Cayman Chemical Company; Ann Arbor, MI) stock solutions (5 mM) were prepared in methanol, and aqueous solutions were prepared fresh before each experiment (1.2 μg/intratracheal dose). Ceramide C6 (N‐hexanoyl‐D‐erythro‐sphingosine) was obtained from Avanti Polar Lipids (Alabaster, AL), mouse GM‐CSF was acquired from PeproTech(Rocky Hill, NJ), and RPMI and serine‐free MEM were purchased from Gibco (Carsbad, CA). Normal human bronchial epithelial cells (NHBE) were obtained from Lonza (Walkerville, MD) and cultured per the manufacturer's instructions. Murine bone marrow‐derived dendritic cells (BMDCs) were generated as previously described .
Pulmonary SPT inhibition enhances airway hyper‐responsivenessAllergen‐induced AHR is a robust physiologic end‐point for quantitating the influence of bioactive compounds on the pathophysiology of allergic asthma. Using a well‐characterized murine model of HDM‐induced AHR, we investigated the biochemical and physiologic effects of intratracheal myriocin on lung lipid content, lung function, and airway structure (treatment protocol outlined in Fig. A). Similar to other investigators, we administered a low dose of intratracheal HDM extract, which sub‐maximally induces AHR and airway inflammation, thus increasing our ability to detect additive and synergistic effects , , , . First, we performed AHR measurement on mice after eight serial doses of intratracheal myriocin and did not detect a significant rise in AHR compared with vehicle‐treated control mice (Fig. B) despite a sustained reduction in lung ceramide levels (Fig. C). Next, we performed histologic examination of lung tissue from myriocin‐treated mice, which showed normal bronchial and alveolar architecture, similar to vehicle‐treated mice (Fig. A vs. D).
Pulmonary SPT inhibition enhances airway hyper‐responsivenessAfter establishing that intratracheal myriocin does not induce significant AHR in our system, we compared the effect of HDM/myriocin co‐administration with that of HDM alone and found that co‐administration significantly enhanced AHR (p < 0.001) (Fig. B). Myriocin's effect on lung ceramide levels, however, was undetectable in animals co‐treated with HDM/myriocin (Fig. C,Supplemental Fig. S1B). Lung histology from both HDM only and HDM/myriocin‐treated mice revealed similar levels of peribronchial inflammatory infiltrates (Fig. B vs. E) and goblet cell metaplasia (Fig. C vs. F, Supplementary Fig. S1C). Goblet cell gene expression analysis revealed that HDM exposure induced multiple asthma‐associated transcripts, including chloride channel calcium‐activated 1 (Clca1/Gob‐5), mucin 5, subtypes A and C, tracheobronchial/gastric (Muc5ac), intelectin 1 (Itln1), and intelectin 2 (Itln2/B). Compared to HDM alone, HDM/myriocin co‐administration enhanced Itln1 and Itln2 expression, had no effect on Clca1, and significantly decreased Muc5ac expression. Therefore, in an allergic model of asthma, myriocin‐treatment is associated with enhanced HDM‐induced AHR and an altered goblet cell gene expression pattern.
Artikelns licens · ActiQs sammanfattningar och texturval är bearbetningar av källan.